Elibol's Suturless LVAD Implantation
Patent Application No: TR2019/23195
International Application No: PCT/TR2020/051248
Designed in 2018, the device was recognized as a finalist for the prestigious Founder Member Dr. Subramanian Innovation Award at the 2020 congress of the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS).
The innovative nature of the device was further validated by the Turkish Patent Institute, which deemed it eligible for patent approval in 2021 based on national and international examination reports. The Turkish patent process was completed in 2024 with the issuance of an examined patent certificate. The international patenting processes are expected to be finalized soon.
Left Ventricular Assist Devices (LVADs) are considered a standard approach in the treatment of end-stage heart failure patients. However, the surgical methods for implanting these devices into the heart lack a standardized protocol and vary between centers. Currently, LVADs are typically secured to the apex of the heart using surgical sutures. This technique carries significant risks of complications such as bleeding, positional instability, and thrombus formation.
Elibol’s Sutureless LVAD Implantation Device offers an innovative solution that enables the implantation of cardiac support pumps into the heart without the use of surgical sutures, while ensuring complete bleeding control. Additionally, this device significantly reduces the duration of the surgical procedure.